◀ Back to HSP90AA1
HSP90AA1 — SNX4
Text-mined interactions from Literome
Okawa et al., Blood 2009
(Leukemia...) :
SNX-2112 , a selective
Hsp90 inhibitor , potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Zhai et al., J Pharm Biomed Anal 2010
:
Determination of
SNX-2112 , a selective
Hsp90 inhibitor , in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats
Bachleitner-Hofmann et al., Clin Cancer Res 2011
:
The aim of our study was to assess the efficacy of
SNX-2112 , a synthetic
HSP-90 inhibitor , in 3 different MET amplified tumor cell lines ( GTL-16, MKN-45, and EBC-1 ) as well as PR-GTL-16 cells, a GTL-16 subline selected for resistance to the highly selective MET kinase inhibitor PHA-665752
Zhai et al., Biomed Pharmacother 2011
:
Preclinical pharmacokinetic analysis of
SNX-2112 , a novel
Hsp90 inhibitor , in rats